https://www.bioworld.com/rss en-us Island Pharmaceuticals Ltd. has secured government and ethics approvals to deploy its investigational antiviral galidesivir in patients infected during the escalating Bundibugyo Ebola outbreak in Africa, giving the small Australian biotech a rare opportunity to collect prospective human data in an active filovirus emergency. http://www.bioworld.com/articles/732432 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732432-island-pharma-targets-ebola-species-lacking-approved-treatments Ebola virus Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary. http://www.bioworld.com/articles/732430 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732430-astrazeneca-nabs-pde3-4-inhibitor-for-copd-in-21b-sino-deal Red lungs on blue background The House Select Committee on China launched an investigation into clinical trials involving U.S. companies that are conducted at Chinese military hospitals and in Xinjiang, China. http://www.bioworld.com/articles/732477 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732477-some-clinical-trials-in-china-under-us-congressional-scrutiny China and U.S. flags Despite the Biosecure Act’s five-year wind-down period that isn’t expected to start until mid-2028, Wuxi Apptec is already feeling the repercussions of being added last month to the U.S. Department of War’s Section 1260H list. http://www.bioworld.com/articles/732475 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732475-wuxi-apptec-seeks-immediate-relief-from-us-listing Legal scales and clipboard Regenerative medicine company Bellaseno GmbH is accelerating development of its absorbable breast scaffold, with a pivotal Australian trial recruiting faster than expected and a newly announced licensing deal with Johnson & Johnson subsidiary Mentor Worldwide LLC positioning the technology for global commercialization. http://www.bioworld.com/articles/732474 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732474-bellaseno-speeds-breast-scaffold-trial-as-j-and-j-deal-clears-path-to-market Illustration of Bellaseno's scaffold placed in the breast Bellaseno’s regenerative absorbable breast scaffold. Credit: Bellaseno. Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732472 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732472-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.” BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.”]]> http://www.bioworld.com/articles/732471 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732471-behind-chinas-retractions-a-paper-mill-economy-built-on-incentives China in red on globe As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. http://www.bioworld.com/articles/732470 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732470-china-trial-retractions-put-data-transparency-in-spotlight Magnifying glass atop paperwork Astrazeneca plc has returned to China’s CSPC Pharmaceutical Group Ltd. for another discovery collaboration, this time in a deal worth up to $1.77 billion to use CSPC’s siRNA drug discovery platform and extrahepatic targeted delivery technology to develop small nucleic acid drug candidates. http://www.bioworld.com/articles/732469 Tue, 07 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732469-astrazeneca-returns-to-tap-chinas-cspc-in-17b-discovery-deal Deal illustration Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). http://www.bioworld.com/articles/732473 Tue, 07 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732473-hk-biotech-listings-gain-traction-in-q2-with-trio-of-june-ipos HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Samsung Bioepis Co. Ltd. announced positive top-line phase I and phase III data for SB-27, a proposed biosimilar to Merck & Co. Inc.’s blockbuster immunotherapy Keytruda (pembrolizumab). Preliminary analysis of parallel-run global phase I and phase III studies demonstrated SB-27’s clinical and pharmacokinetic (PK) equivalence to the reference product, according to a company announcement. http://www.bioworld.com/articles/732351 Tue, 07 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732351-samsung-bioepis-keytruda-biosimilar-hits-phase-i-iii-endpoints Targets with arrows Astrazeneca plc has returned to China’s CSPC Pharmaceutical Group Ltd. for another discovery collaboration, this time in a deal worth up to $1.77 billion to use CSPC’s siRNA drug discovery platform and extrahepatic targeted delivery technology to develop small nucleic acid drug candidates. http://www.bioworld.com/articles/732396 Mon, 06 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732396-astrazeneca-returns-to-tap-chinas-cspc-in-17b-discovery-deal Deal illustration To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.” BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.”]]> http://www.bioworld.com/articles/732415 Fri, 03 Jul 2026 09:00:20 -0400 https://www.bioworld.com/articles/732415-behind-chinas-retractions-a-paper-mill-economy-built-on-incentives China in red on globe Despite the Biosecure Act’s five-year wind-down period that isn’t expected to start until mid-2028, Wuxi Apptec is already feeling the repercussions of being added last month to the U.S. Department of War’s Section 1260H list. Instead of just waiting for its June 11 challenge to its listing as a “Chinese military company” to play out in court, the Shanghai-based contract research, development and manufacturing organization (CRDMO) is now seeking a preliminary injunction to suspend the designation during the court proceedings. http://www.bioworld.com/articles/732276 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732276-wuxi-apptec-seeks-immediate-relief-from-us-listing Legal scales and clipboard Regenerative medicine company Bellaseno GmbH is accelerating development of its absorbable breast scaffold, with a pivotal Australian trial recruiting faster than expected and a newly announced licensing deal with Johnson & Johnson subsidiary Mentor Worldwide LLC positioning the technology for global commercialization. http://www.bioworld.com/articles/732275 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732275-bellaseno-speeds-breast-scaffold-trial-as-j-and-j-deal-clears-path-to-market Illustration of Bellaseno's scaffold placed in the breast Bellaseno’s regenerative absorbable breast scaffold. Credit: Bellaseno. To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.” BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.”]]> http://www.bioworld.com/articles/732273 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732273-behind-chinas-retractions-a-paper-mill-economy-built-on-incentives China in red on globe Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732271 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732271-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. http://www.bioworld.com/articles/732394 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732394-china-trial-retractions-put-data-transparency-in-spotlight Magnifying glass atop paperwork The House Select Committee on China launched an investigation into clinical trials involving U.S. companies that are conducted at Chinese military hospitals and in Xinjiang, China. http://www.bioworld.com/articles/732259 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732259-some-clinical-trials-in-china-under-us-congressional-scrutiny China and U.S. flags As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. http://www.bioworld.com/articles/732258 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732258-china-trial-retractions-put-data-transparency-in-spotlight Magnifying glass atop paperwork Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). http://www.bioworld.com/articles/732393 Wed, 01 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732393-hk-biotech-listings-gain-traction-in-q2-with-trio-of-june-ipos HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Nature Medicine has retracted a widely publicized Chinese lung cancer study that suggested administering immunotherapy before 3 p.m. could dramatically improve survival in a decision that comes amid heightened scrutiny of research integrity and data transparency in high-impact biomedical journals. Nature Medicine has retracted a widely publicized Chinese lung cancer study that suggested administering immunotherapy before 3 p.m. could dramatically improve survival in a decision that comes amid heightened scrutiny of research integrity and data transparency in high-impact biomedical journals.]]> http://www.bioworld.com/articles/732353 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732353-high-profile-retraction-tests-confidence-in-china-led-studies Retraction spelled out on typewriter Otsuka Pharmaceutical Co. Ltd. reported another clinical study win with once-daily centanafadine, a non-stimulant compound targeting attention deficit hyperactivity disorder (ADHD). Top-line results of a dedicated phase IIIb study in patients with ADHD and comorbid anxiety found that centanafadine met the primary endpoint, defined as score improvements on the Adult Investigator Symptom Rating Scale, compared with placebo at week 8. http://www.bioworld.com/articles/732352 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732352-otsukas-centanafadine-scores-in-adhd-comorbid-anxiety-trial Illustration of woman with anxiety, ADHD The oversubscribed $330 million series B round secured by Ollin Biosciences Inc. marks more than another large venture round in ophthalmology. It also highlights an emerging biotech financing model in which Chinese pharma companies discover and clinically validate promising drugs before handing global development to well-capitalized U.S. startups backed by blue-chip venture investors. http://www.bioworld.com/articles/732350 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732350-ollins-330m-series-b-underscores-rise-of-china-origin-newco-model Close-up of a human eye featuring a dollar sign in the iris Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results. http://www.bioworld.com/articles/732349 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732349-corxel-vincentages-oral-glp-1-meets-phase-ii-obesity-endpoints Glass of water and tablets Nuvectis Pharma Inc.’s shares climbed further after the oncology-focused biotech nabbed select rights to a late-stage complement factor B inhibitor (HSK-39297/NXP-100) and a phase I BRAF inhibitor (HSK-42360/NXP-200) from Haisco Pharmaceutical Group Co. Ltd. for $40 million up front. http://www.bioworld.com/articles/732348 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732348-nuvectis-shares-continue-to-rally-after-146b-haisco-deal Dollar symbol with arrow graph Abbisko Therapeutics Co. Ltd. has entered a research collaboration and license agreement with Eli Lilly and Co. to discover and develop innovative medicines across multiple targets, with the aim of advancing novel drug candidates with global potential. http://www.bioworld.com/articles/732347 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732347-lilly-taps-abbisko-for-19b-discovery-deal Microscope The academic authors of the paper describing the pivotal trial of Amgen Inc.’s Tavneos (avacopan) have retracted it from The New England Journal of Medicine because the primary endpoint assessments of nine patients were “re-adjudicated” after the database was locked and the study unblinded. The New England Journal of Medicine because the primary endpoint assessments of nine patients were “re-adjudicated” after the database was locked and the study unblinded.]]> http://www.bioworld.com/articles/732242 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732242-nejm-paper-on-tavneos-pivotal-trial-retracted-by-academic-authors Photo of pen and marker on science journal article A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell engager (TCE) for autoimmune disorders in a potential $1.62 billion deal. http://www.bioworld.com/articles/732310 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732310-deerfield-backed-boulevard-metis-pen-16b-trispecific-tce-deal Handshake, businessmen holding dollar sign, lightbulb Samsung Bioepis Co. Ltd. announced positive top-line phase I and phase III data for SB-27, a proposed biosimilar to Merck & Co. Inc.’s blockbuster immunotherapy Keytruda (pembrolizumab). Preliminary analysis of parallel-run global phase I and phase III studies demonstrated SB-27’s clinical and pharmacokinetic (PK) equivalence to the reference product, according to a company announcement. http://www.bioworld.com/articles/732230 Mon, 29 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732230-samsung-bioepis-keytruda-biosimilar-hits-phase-i-iii-endpoints Targets with arrows